LogicBio Therapeutics (LOGC) PT Lowered to $6 at Chardan Capital Markets, Following Clinical Business Update Feb 2, 2022 02:41PM
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Oct 5, 2020 11:12AM
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Oct 5, 2020 11:12AM
LogicBio Therapeutics (LOGC) Prices 7M Share Public Offering of Common Stock at $6/Each Oct 1, 2020 09:12AM
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock Oct 1, 2020 09:10AM


Oct 1, 2020 09:09AM LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
Sep 30, 2020 04:02PM LogicBio Therapeutics (LOGC) Announces Proposed Common Offering
Sep 30, 2020 04:01PM LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
Sep 30, 2020 04:01PM LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
Sep 25, 2020 07:47PM LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020
Sep 25, 2020 07:47PM LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020
Sep 26, 2019 08:00AM LogicBio Therapeutics to Present at October Conferences
Sep 26, 2019 08:00AM LogicBio Therapeutics to Present at October Conferences
Nov 13, 2018 06:47AM Chardan Capital Markets Starts LogicBio Therapeutics (LOGC) at Buy
Oct 23, 2018 04:05PM LogicBio Therapeutics Announces Closing of Initial Public Offering
Oct 23, 2018 04:05PM LogicBio Therapeutics Announces Closing of Initial Public Offering
Oct 22, 2018 04:00PM Chardan Serves as Lead Manager for LogicBio Therapeutics